Patents by Inventor James Staunton
James Staunton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7807418Abstract: A hybrid type I polyketide synthase gene typically containing a starter module and a plurality of heterologous extender modules is used to synthesise novel polyketides. It is preferably under the control of type II polypolyketide synthase promoter e.g. act I or S. coelicolor.Type: GrantFiled: July 12, 2004Date of Patent: October 5, 2010Assignee: Biotica Technology LimitedInventors: Peter Francis Leadlay, James Staunton, Jesus Cortes
-
Publication number: 20090104666Abstract: The present invention relates to hybrid glycosylated products, and in particular, to natural products such as polyketides and glycopeptides, and to processes for their preparation. The invention is particularly concerned with recombinant cells in which a cloned microbial glycosyltransferase can be conveniently screened for its ability to generate specific glycosylated derivatives when supplied with polyketide, peptide, or polyketide-peptides as substrates. The invention demonstrates that cloned glycosyltransferases when rapidly screened for their ability to attach a range of activated sugars to a range of exogenously supplied or endogenously generated aglycone templates, show a surprising flexibility towards both aglycone and sugar substrates, and that this process allows the production of glycosylated polyketides in good yield.Type: ApplicationFiled: December 18, 2008Publication date: April 23, 2009Inventors: Peter Francis Leadlay, James Staunton, Sapine Gaisser
-
Patent number: 7482137Abstract: The present invention relates to hybrid glycosylated products, and in particular, to natural products such as polyketides and glycopeptides, and to processes for their preparation. The invention is particularly concerned with recombinant cells in which a cloned microbial glycosyltransferase can be conveniently screened for its ability to generate specific glycosylated derivatives when supplied with polyketide, peptide, or polyketide-peptides as substrates. The invention demonstrates that cloned glycosyltransferases when rapidly screened for their ability to attach a range of activated sugars to a range of exogenously supplied or endogenously generated aglycone templates, show a surprising flexibility towards both aglycone and sugar substrates, and that this process allows the production of glycosylated polyketides in good yield.Type: GrantFiled: October 12, 2006Date of Patent: January 27, 2009Assignee: Biotica Technology LimitedInventors: Peter Francis Leadlay, James Staunton, Sabine Gaisser
-
Publication number: 20080287483Abstract: The rapamycin gene cluster is an example of a gene cluster which includes a gene (rapL) leading to the formation of a precursor compound (pipecolic acid, in this case) which is required for inclusion in the larger product (rapamycin) produced by the enzymes encoded by the cluster. We have produced a mutant strain containing a rapamycin gene cluster in which the rapL gene is disabled. The strain does not naturally produce rapamycin but does so if fed with pipecolic acid. By feeding with alternative carboxylic acids we have produced variants of rapamycins. Tests have shown biological activity.Type: ApplicationFiled: May 29, 2008Publication date: November 20, 2008Inventors: Peter Francis Leadlay, James Staunton, Lake Ee Khaw
-
Patent number: 7381546Abstract: The rapamycin gene cluster is an example of a gene cluster which includes a gene (rapL) leading to the formation of a precursor compound (pipecolic acid, in this case) which is required for inclusion in the larger product (rapamycin) produced by the enzymes encoded by the cluster. We have produced a mutant strain containing a rapamycin gene cluster in which the rapL gene is disabled. The strain does not naturally produce rapamycin but does so if fed with pipecolic acid. By feeding with alternative carboxylic acids we have produced variants of rapamycins. Tests have shown biological activity.Type: GrantFiled: January 10, 2006Date of Patent: June 3, 2008Assignee: Biotica Technology LimitedInventors: Peter Francis Leadlay, James Staunton, Lake Ee Khaw
-
Publication number: 20070092944Abstract: The present invention relates to hybrid glycosylated products, and in particular, to natural products such as polyketides and glycopeptides, and to processes for their preparation. The invention is particularly concerned with recombinant cells in which a cloned microbial glycosyltransferase can be conveniently screened for its ability to generate specific glycosylated derivatives when supplied with polyketide, peptide, or polyketide-peptides as substrates. The invention demonstrates that cloned glycosyltransferases when rapidly screened for their ability to attach a range of activated sugars to a range of exogenously supplied or endogenously generated aglycone templates, show a surprising flexibility towards both aglycone and sugar substrates, and that this process allows the production of glycosylated polyketides in good yield.Type: ApplicationFiled: October 12, 2006Publication date: April 26, 2007Inventors: Peter Leadlay, James Staunton, Sabine Gaisser
-
Patent number: 7198922Abstract: A polyketide synthase (“PKS”) of Type I is a complex multienzyme including a loading domain linked to a multiplicity of extension domains. The first extension module receives an acyl starter unit from the loading domain and each extension module adds a further ketide unit which may undergo processing (e.g. reduction). We have found that the Ksq domain possessed by some PKS's has decarboxylating activity, e.g. generating (substituted) acyl from (substituted) malonyl. The CLF domain of type II PKS's has similar activity. By inserting loading modules including such domains into PKS's not normally possessing them it is possible to control the starter units used.Type: GrantFiled: February 19, 2004Date of Patent: April 3, 2007Assignees: Biotica Technology Limited, Pfizer, Inc.Inventors: Peter Francis Leadlay, James Staunton, Jesus Cortes, Hamish Alastair Irvine McArthur
-
Patent number: 7148045Abstract: A polyketide synthase (“PKS”) of Type I is a complex multienzyme including a loading domain linked to a multiplicity of extension domains. The first extension module receives an acyl starter unit from the loading domain and each extension module adds a further ketide unit which may undergo processing (e.g. reduction). We have found that the Ksq domain possessed by some PKS's has decarboxylating activity, e.g. generating (substituted) acyl from (substituted) malonyl. The CLF domain of type II PKS's has similar activity. By inserting loading modules including such domains into PKS's not normally possessing them it is possible to control the starter units used.Type: GrantFiled: June 29, 1999Date of Patent: December 12, 2006Assignee: Biotica Technology LimitedInventors: Peter Francis Leadlay, James Staunton, Jesus Cortes, Hamish Alastair Irvine McArthur
-
Publication number: 20060240528Abstract: A polyketide synthase (“PKS”) of Type I is a complex multienzyme including a loading domain linked to a multiplicity of extension domains. The first extension module receives an acyl starter unit from the loading domain and each extension module adds a further ketide unit which may undergo processing (e.g. reduction). We have found that the Ksq domain possessed by some PKS's has decarboxylating activity, e.g. generating (substituted) acyl from (substituted) malonyl. The CLF domain of type II PKS's has similar activity. By inserting loading modules including such domains into PKS's not normally possessing them it is possible to control the starter units used.Type: ApplicationFiled: April 21, 2006Publication date: October 26, 2006Inventors: Peter Leadlay, James Staunton, Jesus Cortes, Hamish Irvine McArthur
-
Publication number: 20060105436Abstract: The rapamycin gene cluster is an example of a gene cluster which includes a gene (rapL) leading to the formation of a precursor compound (pipecolic acid, in this case) which is required for inclusion in the larger product (rapamycin) produced by the enzymes encoded by the cluster. We have produced a mutant strain containing a rapamycin gene cluster in which the rapL gene is disabled. The strain does not naturally produce rapamycin but does so if fed with pipecolic acid. By feeding with alternative carboxylic acids we have produced variants of rapamycins. Tests have shown biological activity.Type: ApplicationFiled: January 10, 2006Publication date: May 18, 2006Inventors: Peter Leadlay, James Staunton, Lake Khaw
-
Patent number: 7018808Abstract: The rapamycin gene cluster is an example of a gene cluster which includes a gene (rapL) leading to the formation of a precursor compound (pipecolic acid, in this case) which is required for inclusion in the larger product (rapamycin) produced by the enzymes encoded by the cluster. We have produced a mutant strain containing a rapamycin gene cluster in which the rapL gene is disabled. The strain does not naturally produce rapamycin but does so if fed with pipecolic acid. By feeding with alternative carboxylic acids we have produced variants of rapamycins. Tests have shown biological activity.Type: GrantFiled: December 2, 2002Date of Patent: March 28, 2006Assignee: Biotica Technology LimitedInventors: Peter Francis Leadlay, James Staunton, Lake Ee Khaw
-
Patent number: 7001747Abstract: Nucleic acid molecules encoding at least part of a Type I polyketide synthase, and having a polylinker with multiple restriction enzyme sites in place of one or more PKS genes encoding enzymes associated with reduction, optionally further including nucleic acid incorporated into the polylinker, the further nucleic acid encoding one or more reductive enzymes; plasmids incorporating such nucleic acids; host cells transfected with such plasmids; methods relating thereto.Type: GrantFiled: July 6, 1999Date of Patent: February 21, 2006Assignees: Biotica Technology Limited, Pfizer, Inc.Inventors: Johannes Kellenberger, Peter Francis Leadlay, James Staunton, Kim Jonelle Stutzman-Engwall, Hamish Alastair Irvine McArthur
-
Patent number: 6960453Abstract: A hybrid type I polyketide synthase gene typically containing a starter module and a plurality of heterologous extender modules is used to synthesize novel polyketides. It is preferably under the control of a type II polypolyketide synthase promoter e.g. act I of S. coelicolor.Type: GrantFiled: July 4, 1997Date of Patent: November 1, 2005Assignee: Biotica Technology LimitedInventors: Peter Francis Leadlay, James Staunton, Jesus Cortes
-
Publication number: 20050089982Abstract: A hybrid type I polyketide synthase gene typically containing a starter module and a plurality of heterologous extender modules is used to synthesise novel polyketides. It is preferably under the control of type II polypolyketide synthase promoter e.g. act I or S.coelicolor.Type: ApplicationFiled: July 12, 2004Publication date: April 28, 2005Inventors: Peter Leadlay, James Staunton, Jesus Cortes
-
Publication number: 20050090461Abstract: A polyketide synthase (“PKS”) of Type I is a complex multienzyme including a loading domain linked to a multiplicity of extension domains. The first extension module receives an acyl starter unit from the loading domain and each extension module adds a further ketide unit which may undergo processing (e.g. reduction). We have found that the Ksq domain possessed by some PKS's has decarboxylating activity, e.g. generating (substituted) acyl from (substituted) malonyl. The CLF domain of type II PKS's has similar activity. By inserting loading modules including such domains into PKS's not normally possessing them it is possible to control the starter units used.Type: ApplicationFiled: February 19, 2004Publication date: April 28, 2005Inventors: Peter Leadlay, James Staunton, Jesus Cortes, Hamish McArthur
-
Publication number: 20040219645Abstract: The complete sequence of the gene cluster for the monensin type I polyketide synthase, from S. cinnamonensis, is provided. Thus variant polyketides containing monensin-derived elements can be genetically engineered. Furthermore there are novel features, e.g. a regulatory protein mon RI, which are of wide utility.Type: ApplicationFiled: May 6, 2002Publication date: November 4, 2004Inventors: Peter Francis Leadley, James Staunton, Mark Yan Oliynyk
-
Publication number: 20030203425Abstract: The present invention relates to hybrid glycosylated products, and in particular, to natural products such as polyketides and glycopeptides, and to processes for their preparation. The invention is particularly concerned with recombinant cells in which a cloned microbial glycosyltransferase can be conveniently screened for its ability to generate specific glycosylated derivatives when supplied with polyketide, peptide, or polyketide-peptides as substrates. The invention demonstrates that cloned glycosyltransferases when rapidly screened for their ability to attach a range of activated sugars to a range of exogenously supplied or endogenously generated aglycone templates, show a surprising flexibility towards both aglycone and sugar substrates, and that this process allows the production of glycosylated polyketides in good yield.Type: ApplicationFiled: March 25, 2003Publication date: October 30, 2003Inventors: Peter Francis Leadlay, James Staunton, Sabine Gaisser
-
Publication number: 20030104585Abstract: The rapamycin gene cluster is an example of a gene cluster which includes a gene (rapL) leading to the formation of a precursor compound (pipecolic acid, in this case) which is required for inclusion in the larger product (rapamycin) produced by the enzymes encoded by the cluster. We have produced a mutant strain containing a rapamycin gene cluster in which the rapL gene is disabled. The strain does not naturally produce rapamycin but does so if fed with pipecolic acid. By feeding with alternative carboxylic acids we have produced variants of rapamycins. Tests have shown biological activity.Type: ApplicationFiled: December 2, 2002Publication date: June 5, 2003Inventors: Peter Francis Leadlay, James Staunton, Lake Ee Khaw
-
Patent number: 6437151Abstract: Erythromycins, particularly ones with novel C-13 substituents R1 (e.g. C3-C6 cycloalkyl or cycloalkenyl groups) are prepared by fermenting suitable organisms in the presence of R1CO2H. A preferred organism is Saccharopolyspora erythraea preferably containing an integrated plasmid capable of directing synthesis of desired compounds.Type: GrantFiled: June 29, 2001Date of Patent: August 20, 2002Assignees: Biotica Technology Limited, Pfizer Inc.Inventors: Peter Francis Leadlay, James Staunton, Jesus Cortes, Michael Stephen Pacey
-
Publication number: 20020004487Abstract: Erythromycins, particularly ones with novel C-13 substituents R1 (e.g. C3-C6 cycloalkyl or cycloalkenyl groups) are prepared by fermenting suitable organisms in the presence of R1CO2H. A preferred organism is Saccharopolyspora erythraea preferably containing an integrated plasmid capable of directing synthesis of desired compounds.Type: ApplicationFiled: June 29, 2001Publication date: January 10, 2002Inventors: Peter Francis Leadlay, James Staunton, Jesus Cortes, Michael Stephen Pacey